Tirzepatide reduces the risk of diabetes progression by 94%

On November 13, 2024, Lilly announced the latest follow-up data of Phase III clinical SURBOUNT-1 of Tirzepatide in the treatment of pre diabetes patients with obesity or overweight. The follow-up time was up to 3 years (176 weeks), and the data were also published in the New England Medical Journal.

After 176 weeks of treatment, the proportion of patients who progressed to type 2 diabetes in the Tirzepatide treatment group and the placebo control group was 1.2% and 12.6% respectively, and the risk of progression to type 2 diabetes was reduced by 94%. After 17 weeks of drug withdrawal, the rates of progression to type 2 diabetes were 2.4% and 13.7%, respectively, and the risk of progression to type 2 diabetes was reduced by 88%. After drug withdrawal, the proportion of patients who progressed to type 2 diabetes increased rapidly, indicating that the disease progression was delayed but may not be fundamentally reversed. Nevertheless, it is still of great significance to delay the progress of type 2 diabetes.

In terms of weight, the placebo group, 5mg, 10mg, and 15mg Tirzepatide treatment groups lost 1.3%, 12.3%, 18.7%, and 19.7%, respectively.

eight

About Tirzepatide

Tirzepatide is a dual agonist of glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor, which can simultaneously activate GLP-1 receptor and GIP receptor-mediated signaling pathways. GIP and GLP-1 are natural intestinal insulinotropic hormones that regulate blood sugar. Tirzepatide was approved by the US FDA (trade name: Mounjaro) in May 2022 for use in combination with diet control and exercise to improve the blood sugar control of adult type 2 diabetes patients. Last November, tirzepatide received FDA approval again (trade name: Zepbound) for the purpose of reducing weight and maintaining weight stability in obese or overweight adult patients.